Lessons from innovation in drug-device combination products by Couto, Daniela S. et al.
  	

Lessons from innovation in drug-device combination products
Daniela S. Couto, Luis Perez-Breva, Pedro Saraiva, Charles L. Cooney
PII: S0169-409X(11)00277-8
DOI: doi: 10.1016/j.addr.2011.10.008
Reference: ADR 12205
To appear in: Advanced Drug Delivery Reviews
Received date: 8 June 2011
Accepted date: 29 October 2011
Please cite this article as: Daniela S. Couto, Luis Perez-Breva, Pedro Saraiva, Charles
L. Cooney, Lessons from innovation in drug-device combination products, Advanced Drug
Delivery Reviews (2011), doi: 10.1016/j.addr.2011.10.008
This is a PDF ﬁle of an unedited manuscript that has been accepted for publication.
As a service to our customers we are providing this early version of the manuscript.
The manuscript will undergo copyediting, typesetting, and review of the resulting proof
before it is published in its ﬁnal form. Please note that during the production process
errors may be discovered which could aﬀect the content, and all legal disclaimers that
apply to the journal pertain.
AC
CE
PT
ED
 M
AN
US
CR
IP
T
ACCEPTED MANUSCRIPT
1 
Lessons from Innovation in Drug-Device Combination Products  
 
Daniela S. Coutoa,b,c*, Luis Perez-Brevaa,d , Pedro Saraivae, Charles L. Cooneya 
 
Abstract 
Drug-device combination products introduced a new dynamic on medical product 
development, regulatory approval, and corporate interaction that provide valuable lessons 
for the development of new generations of combination products. This paper examines the 
case studies of drug-eluting stents and transdermal patches to facilitate a detailed 
understanding of the challenges and opportunities introduced by combination products 
when compared to previous generations of traditional medical or drug delivery devices. Our 
analysis indicates that the largest barrier to introduce a new kind of combination products is 
the determination of the regulatory center that is to oversee its approval. The first product 
of a new class of combination products offers a learning opportunity for the regulator and 
the sponsor. Once that first product is approved, the leading regulatory center is 
determined, and the uncertainty about the entire class of combination products is drastically 
reduced. The sponsor pioneering a new class of combination products assumes a central  
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role in reducing this uncertainty by advising the decision on the primary function of the 
combination product. Our analysis also suggests that this decision influences the nature 
(pharmaceutical, biotechnology, or medical devices) of the companies that will lead the 
introduction of these products into the market, and guide the structure of corporate 
interaction thereon.  
 
Keywords: controlled drug delivery; transdermal patches; drug-eluting stents, primary 
mode of action 
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1. Introduction 
Combination products of drugs and devices have been in the market for more than half-
century1. Early examples of combination products seem to have required little interaction 
between the pharmaceutical and medical device industries. However, the increasingly 
sophisticated combination products brought to market over the last couple of decades [1] 
have furthered the need to develop drugs and devices collaboratively using resources from 
both industries. Classifying the resulting high-value combination products as either enabled 
drugs or enabled devices has become a challenge. Over the last decade, regulatory agencies 
have developed specific competences and regulations that address the increasing integration 
of drugs and devices observed in the latest generation of combination products. For 
example, the Food and Drug Administration (FDA) established the Office of Combination 
Products on December 24, 2002, according to the Congress enactment. The Medical Device 
User Fee and Modernization Act enacted by the Congress on October 26, 2002 [2], required 
the FDA to establish an office “to ensure the prompt assignment of combination products to 
agency centers, the timely and effective premarket review of such products, and consistent 
and appropriate postmarket regulation of” combination products. The Office of 
Combination Products is committed to support industry and FDA staff in “understanding 
this complex regulatory area” [3].  
High-value combination products range from drug-eluting stents to transdermal patches. 
Despite their high market potential, high-value combination products present new 
technological and organizational challenges: they require new product development  
_______________ 
1 The metered-dose inhaler, developed in 1955 by the Riker Laboratories, is one of the earliest examples of 
combination products. 
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strategies and a new regulatory approach  compared to traditional combination products, 
drugs, and devices. Traditional combination products were driven by the need to bring 
more convenient products to the final user and include prefilled insulin pens and condoms 
with spermicidal activity. The lack of a competitive advantage emerging from the 
combination itself precipitated the rapid progression of these products into widely available 
undifferentiated commodity products. By comparison, high-value combination products 
extract their competitive advantage from the technological sophistication of the 
combination and aim at enhancing the function of the medical device or drug. 
New regulations have contributed to clarify the approval process of high-value combination 
products, but have also made it challenging to determine at a glance when a product will be 
considered a combination product. Combination products combine two or three single-
regulated entities: drug, biological and/or medical device. They can be physically, 
chemically, or otherwise combined or mixed and produced as a single entity. They can also 
be packaged together or separately as long as their use comprises the interaction or usage of 
both.  This definition may sometimes lead to certain products being considered as 
combination products against the practitioner intuition (e.g. transdermal patches). In the 
United States (U.S.), the Code of Federal Regulations 21 CFR 3.2(e) defines what should 
be considered as a combination product in more detail.  
In this paper we analyze transdermal patches and drug-eluting stents; both combine a 
device and a drug, but differ in their primary function. The transdermal patch is considered 
a drug with an improved delivery system, while the drug-eluting stent is a device 
functionally enhanced by a drug. In the case of drug-eluting stents, the drug and the device 
had been independently approved for individual administration prior to the approval of the 
drug-eluting stent as a combination product. In the case of transdermal patches, the drug is 
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often approved separately for patient administration, but the patch itself needs not to be 
approved as a device. The patch is perceived as a platform for drug delivery and it is 
arguable whether transdermal patches should be considered combination products. 
However, according to the FDA these examples are regulated as combination products and 
subject to different regulatory paths [2].  
The regulatory agency designates the primary function of a combination product by its 
primary mode of action. In the FDA, the Office of Combination Products receives the 
combination product, determines its primary mode of action, and based on that assessment, 
re-directs it to the most adequate FDA center to proceed with the regulatory evaluation [2]. 
For example, the primary mode of action of a drug-eluting stent is device. Consequently, 
regulatory evaluation of drug-eluting stents is conducted by the Center for Devices and 
Radiological Health.  
There are salient differences between how regulators assess primary mode of action and 
how it may be done pharmacologically. The latter is the mechanism by which a 
pharmacologically active substance binds to a molecular target affecting the biological or 
biochemical pathway inside a living organism. The former – and the one we will use 
throughout this paper –  is a regulatory assessment of the primary function of the 
combination product. 
The paper is organized as follows, after a brief overview of the sources of data and the 
methodology we followed, we examine the spectrum of combination products with an 
overview of drug-eluting stents and transdermal patches. We dive into those two examples 
further to analyze the evolution from the original device/drug into a combination product: 
from stents into drug-eluting stents; and the emergence of drug delivery systems in the 
context of transdermal patches. These two examples anchor our discussion about devices 
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whose function is enhanced with drug delivery and drugs that are delivered more 
effectively through a device platform. This seemingly fine distinction translates into 
completely different regulatory pathways and is at the core of the strategies available to 
companies introducing first-of-a-kind combination products to reduce development 
uncertainty. We discuss further these strategies as we identify the dynamics of innovation 
that drug-device products follow during product development in comparison with 
traditional device or drug development. Along with this discussion we present highlights on 
the data that supports our analysis in side boxes that complement the more comprehensive 
tables available in supplemental materials.  
This discussion leads us to one of the key contributions of this paper: that the assessment of 
the primary mode of action of a combination product – often perceived as a barrier and a 
major source of uncertainty – is in fact a consequence of the kind of company pioneering 
the development process. We summarize this finding with a model that explains the role of 
pioneers, regulators, and incumbents in the development of combination products. This 
model builds on prior work on architectural innovation to motivate how disruptive 
innovation such as combination products relates to technology integration and the 
exploration of adjacent markets. This is a critical insight because it helps understand 
combination products (even transdermal patches) as the result of a sequential evolution that 
can be reproduced in future generations of combination products. 
The paper concludes with highlights on the potential application of our findings and the 
model we propose in the development of new generations of combination drug-device 
products, their regulatory outlook and the strategic considerations for technology and 
market partnerships. This is the second main contribution of this paper to the literature in 
this area. These highlights outline a roadmap for the development of combination products 
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that considers the evolution of combination products as a function of the regulatory, 
technological, and corporate evolution.  
While this work draws mainly from examples from the U.S. market, our preliminary 
analysis of other markets suggests that our conclusions are more general and broadly 
applicable to other geographic markets, as well as to the next generations of combination 
products, such as products resulting from tissue engineering. 
 
2. Methodology 
We listed and analyzed all the drug-eluting stents and controlled drug delivery system 
currently approved by the FDA and that required New Drug Application submission. This 
resulted in 12 drug-eluting stents and over 70 controlled drug delivery systems with market 
approval in the U.S.. We collected data from four types of sources: interviews with experts 
in the field, databases, Orange Book, financial reports and papers, and company websites.  
Information of drug-eluting stent approvals was collected from the FDA website [4], and 
re-examined at the companies websites and financial reports. All the clinical data was 
retrieved from the clinicaltrials.gov database, when searching for each individual sponsor, 
and complemented with scientific publications. All the deals related with the sponsor 
company of each combination product were searched in the recap.com database and 
company websites.  
The table in supplement A lists information on controlled drug delivery systems sorted by 
sponsor company, drug, new drug application (NDA) number, date of approval and 
indications, and description. The information from this list was retrieved from the Orange 
Book [5], and crosschecked and complemented with Drug@FDA database [6]. In the 
Orange Book, we searched for particular dosage forms (all extended release forms, 
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implants, intrauterine devices, and inserts) and routes of administration (implantation, 
intravitreal, intracranial, intramuscular, intrauterine, subcutaneous, and transdermal). For 
each controlled drug delivery system, we complemented the sponsor information with 
information of the company that developed the device platform, the manufacturer, and the 
company currently marketing the combination product. This information was retrieved 
from the drug label approved by the FDA, deals at the recap.com database, and companies‟ 
websites. The analysis of the interactions between different stakeholders is supported by the 
information on the different roles (sponsor, manufacturer, manufacturing, and marketing) 
assumed by companies in different stages of development, as obtained from the 
aforementioned databases. 
 
3. Device Function Improved by Drugs 
Within the past two decades, two different generations of stents were launched into the 
market. The second generation delivered improved results with more sophisticated 
technology that imposed additional manufacturing and regulatory approval challenges. 
Companies that bridged both generations developed the expertise to provide more 
sophisticated medical devices that integrate and deliver drugs. 
In 1994 the FDA approved the first stent – a bare-metal stent. It is an expandable metallic 
device that is deployed inside a stenotic blood vessel to dilate the occlusion using a catheter 
and a driving system. Stenosis occurs due to the formation of an atheromatous plaque 
inside the blood vessel. The stent is applied to improve the blood flow by expanding the 
occlusion. Stents are simple solutions – less invasive and highly deliverable – when 
compared with previous standards of care, such as coronary bypass. Though stents were 
shown to be highly effective and reduce the rate of restenosis, when compared to balloon 
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angioplasty, in-stent restenosis is still a major complication after stent deployment [7,8]. 
Patients with stents may develop stenosis inside of the stent, leading to occlusion of the 
blood vessel again.  
In 2003, less than one decade after the first stent was introduced in the U.S. market, the 
FDA approved the first drug-eluting stent. A drug-eluting stent combines a drug enclosed 
in a polymer that coats the metallic framework, the integration of drug and polymer 
determines the mechanism for controlled drug release [9]. Although technically more 
complex than bare-metal stents, drug-eluting stents have been found to outperform bare-
metal stents [10]. The drug-eluting stent combines the mechanical action on the blood 
vessel blockage with the release of drugs that inhibit restenosis to decrease the problem of 
in-stent restenosis associated with bare-metal stents [11,12]. Since 2003, new drug-eluting 
stents were developed for patients with a broader range of complications associated with 
stenosis, such as multiple lesions, small vessels, long lesions [13], and diabetes [14,15]. 
The additional burdens associated with the integration of technologies, manufacturing, and 
regulatory approval of drug-eluting stents helped the companies that bridged bare-metal 
and drug-eluting stents retain competitive advantage through the development of key 
expertise advancing sophisticated medical devices that integrate and deliver drugs. 
 
4. Drug Delivery Improved by Devices 
Since the 1970s, the FDA has approved over 70 controlled drug delivery combination 
products (see Fig. 1 and Supplement A). By the 1980s ten controlled drug delivery products 
were approved spanning over three categories: transdermal patches, ocular implants, and 
intrauterine devices. During the 1990s as drug-delivery technologies became increasingly 
sophisticated controlled drug delivery products diversified further into: subcutaneous 
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implants, vaginal rings, buccal systems, and wafers (Fig. 1a). Technological sophistication 
enabled new approaches to drug delivery systems beyond transdermal patches to address 
highly specific needs; in particular, therapies that stood to benefit from more invasive drug-
delivery solutions than transdermal drug delivery (see Fig. 1c and Table in Supplement A 
listing all controlled drug delivery products approved by FDA by indication). Gliadel® is 
an example of this technological evolution: Gliadel® is a wafer containing carmustine 
(7.7mg), a chemotherapeutic drug, homogeneously distributed in a biodegradable 
polyanhydride copolymer that is applied inside the brain as an adjunct to surgery for the 
treatment of glioma patients. 
Fig. 1 shows the number of FDA approved controlled drug delivery systems by type of 
system and therapeutic indication. Transdermal patches account for over 60% of all 
controlled drug delivery systems available in the market (Fig. 1b). The technology of 
transdermal patches has been extensively described elsewhere [16-18], here we focus 
instead on the evolution of patches and controlled-drug delivery systems through 
technological generations. 
Transdermal patches offer an alternative for controlled delivery of substances into the 
bloodstream through the skin, that is particularly suited for the delivery of potent drugs that 
may be poorly absorbed – or extensively metabolized – when administered orally. Their 
initial adoption can be explained by their ease-of-use, convenience, and increased patient 
compliance. The first generation of patches only allowed for passive diffusion of the drug 
through the skin, later generations introduced active methods of diffusion. 
The first generation of transdermal patches was essentially limited by the passive methods 
of drug diffusion to deliver small, lipophilic, low-dose drugs [18]. Two different designs 
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competed in this first generation: reservoir-type (regulated by membrane and skin 
permeability) and matrix-type patches (regulated only by skin permeability) [16]. 
The second generation of transdermal patches introduced active methods of diffusion that 
enabled the delivery of larger molecules and improved control over diffusion rates [16]. 
This new generation uses chemical enhancers, noncavitational ultrasound, and 
iontophoresis to facilitate drug delivery [18]. Iontophoretic systems are an example of 
active transdermal patches, active diffusion is achieved with a residual electric current that 
helps widen skin pores and facilitates diffusion of larger molecules through the skin.  
The third generation of patches introduced new active diffusion technologies that cross the 
skin‟s barrier layer of „stratum corneum‟: microneedles, thermal ablation, 
microdermabrasion, electroporation, cavitational ultrasound, and synergistic combinations 
thereon [17-20]. The third generation is currently under clinical trials and is expected to 
revolutionize the delivery of large molecules and vaccines [21,22]. 
 
5. Dynamics of innovation in combination products 
The development of a combination product involves a very specific pattern of interactions 
between several firms and regulatory agencies. Our longitudinal study of drug-eluting 
stents and transdermal patches suggests that the dynamics of innovation in combination 
products can be readily summarized by the roles assumed by pioneer, incumbent, and 
regulatory agency in the product development process and in the determination of the 
primary mode of action. We refer to established firms in the focal market that we are 
studying (medical devices or pharmaceutical) as incumbents. The focal market is the 
market that is either being disrupted by technological change (introduction of combination 
products), or adjacent to it. Pioneers are the sponsors introducing the first of a class of 
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combination product. Fig. 2 illustrates the roles of the pioneer, incumbent, and regulatory 
agency across product development. 
During the development phase, the pioneer licenses complementary technologies and 
integrates them into a full combination product. Subsequent phases are determined by the 
primary mode of action that plays a pivotal role leading into the clinical study phase. Our 
research suggests that the actions assumed by each player before the determination of the 
primary mode of action have a strong bearing on the assessment of the primary mode of 
action. It is these actions that drive the dynamics of innovation in combination products; 
more specifically they drive the development of the technology and product, the reduction 
of regulatory uncertainty, and the structure of corporate partnerships. 
From a technological vantage point, the pioneer acts as an integrator of complementary 
technologies that are generally licensed from third parties. The way in which the pioneer 
chooses to integrate these technologies into the product design shapes corporate 
partnerships and informs the primary mode of action assessment. Corporate interaction with 
technology partners is established through license agreements, and what is claimed in the 
description of the intended use submitted to the regulator advises the primary mode of 
action. 
From a regulatory vantage point, the regulator‟s first task is to determine the center best 
suited to lead and support regulatory approval based on the input from the sponsor and the 
submission documents. That is the determination of the primary mode of action, which 
defines the regulatory approval pathway (medical device, drug, or biologic). This 
assessment has further consequences as it indirectly determines the profile of the incumbent 
that is more likely to advance product development and market launch. 
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From a corporate vantage point, as product development progresses, the incumbents that 
were identified after the primary mode of action assessment take-over gradually from the 
pioneer the role of shaping corporate partnerships. As the product approaches market, 
corporate interactions focus on market rather than technology and the incumbents are 
generally better positioned to select and decide how to market the combination product. 
This phase involves considerations about market, distribution channels, and service 
networks generally available to the incumbent as well as the financial support required to 
pursue regulatory approval and commercialize the combination product.  
Once the first of a class of combination products is marketed, it rapidly becomes a 
dominant standard (for a technology, a product, and a regulatory pathway) allowing other 
incumbents to become fast followers. 
 
5.1. The pioneer sets the path 
Our analysis suggests that pioneers that bring the first product of a class of combination 
products have an impact in the innovation dynamics of the entire class, not just in the 
specifics of the technological integration that led to the combination product. The pioneer 
touches on the three levers that result in the primary mode of action: integrates technologies 
into a new design, frames the regulatory assessment for this product and for the ones that 
will follow, and creates the structure of corporate partnerships through licensing of 
complementary technologies.  
Pioneers are new entrants (firms or independent business units) that prove successful in 
disrupting the industry with the introduction of a new design of combination product. 
Christensen defines disruptive technologies as the ones that bring a different value 
proposition to the market, resulting in typically cheaper, simpler, smaller, and more 
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convenient products and that ultimately precipitate the technology failure of the leading 
firm [23]. Our findings mirror Christensen‟s findings in other industry sectors [23]: 
business units of larger firms are likely to become pioneers when they retain a degree of 
independence and can define its own processes and business model. For this reason, when 
the pioneer is acquired Christensen and Kaufman [24] argue that to continue to promote 
innovation the parent company must preserve the independence of the acquisition instead of 
rushing to integrate it into an existing business unit. 
Alza Corporation (“Alza”) and Cordis Corporation (“Cordis Corp.”) were two pioneers, 
with very specific business competences, that disrupted the industry in their respective area. 
Cordis Corp. released the first bare-metal and drug-eluting stents to the market. Alza led the 
way in developing controlled drug delivery systems, in particular the transdermal patches. 
These two examples are explored in more detail in Box 1.  
 
5.2. Architectural innovation is at the basis of combination products 
Combination products are examples of architectural innovation in the sense described by 
Henderson and Clark [29]. The pioneer, and later the incumbents, license complementary 
technologies and integrate them with its core technology to develop the combination 
product. According to Henderson and Clark architectural innovations keep the core concept 
unchanged and focus on the way in which components of a product are linked together 
[29]. This means that the basic knowledge underlying the core components is unaffected 
too.  
Combination products are architectural innovations because they maintain a core concept 
and reinforce it with sophisticated linkages between the core technology and the 
complementary components are modified.  
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The notion of architectural innovation is critical to understand the impact the profile of the 
company (whether pharmaceutical, biotechnology, or medical devices companies) has at 
the technological level to discriminate core and complementary technologies. The way in 
which drug-eluting stents and controlled drug delivery systems emerges illustrates the 
notion of architectural innovation as it relates to the creation of a combination product. We 
overview this in further detail in Box 2. In the case of drug-eluting stents, the 
complementary technologies (drug and polymer) are licensed and integrated into the device 
platform by the device company. In the case of controlled drug delivery systems, the 
complementary technologies (platform to deliver drug) are licensed and integrated with the 
drug by the drug company. 
Architectural innovation has strong implications on the development of complementary 
skills and the accretion of company infrastructure. In addition to integrating technologies, 
the firm needs new equipment, multidisciplinary know-how and skills, and development of 
new test methods. For instance, drug-eluting stents likely resulted from the work of 
multidisciplinary teams of engineers, biomaterials scientists, pharmaceutical scientists, and 
many different clinical specialists (as inferred by Burt and Hunter [30]). On the other hand, 
testing medical devices typically includes assessing physical and mechanical properties, 
while testing drugs or biologics focus on analytical and bio-analytical chemistry, and 
biological potency tests. The medical device companies that pioneered drug-device 
combination products lack typically the expertise to develop, integrate, and test drugs and 
likely acquired those new competencies typical from the pharmaceutical space while 
integrating drug and device. 
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5.3. Primary function decreases uncertainty 
The primary mode of action plays a pivotal role bridging product development and the 
clinical study phase and in subsequent phases, it correlates with the structure of corporate 
interactions that emerges. Accordingly, the assessment of the primary mode of action is 
often perceived as the single biggest risk-mitigating milestone for combination products. 
However, despite the perceived prominence of the primary mode of action in the process, 
our analysis suggests that it is the actions assumed by each stakeholder, not the assessment 
itself, that drive the dynamics of innovation in combination products. In other words, to an 
external party, the primary mode of action represents a good descriptive indicator that 
clarifies strategy going forward. However, for the pioneer or any of the parties involved in 
the co-development of a new kind of combination product there are ample opportunities to 
predict the primary mode of action from the strategic choices done before the regulator 
does the actual assessment. 
The determination of a primary mode of action narrows the scope of subsequent 
development and clinical milestones in ways that make the combination product more 
appealing to different kinds of incumbents. It will clarify the milestones ahead for an 
incumbent to advance product development and eventually market the combination 
product. If a combination product is considered as device, then a medical device company 
is better positioned – and more likely –  to drive the regulatory approval. The Table in 
Supplement B illustrates this point with a sample list of combination products obtained 
from the webpage of the Office of Combination Products, sorted by the type of the primary 
mode of action (medical device, drug, or biological), and annotated with the clinical 
indication, approval date, and the company that developed it. The data suggests that the 
company sponsoring the product through the regulatory process is the company focused on 
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the core technology that is associated with the primary mode of action. That is, the sponsor 
is a medical device companies when the primary mode of action is a device, biotechnology 
or biopharmaceutical companies when it is a biologic, and pharmaceutical companies when 
it is a drug. 
The determination of a primary mode of action for the first-of-a-kind combination product 
is critical because the regulatory framework for combination products is established by 
precedent: the primary mode of action of the first-of-a-kind sets the precedent for the entire 
class. Subsequent entrants may then perceive that this assessment decreases the uncertainty 
for the entire class. 
In practice this means that the existence of an extra step for the „first-of-a-kind‟ 
combination product increases the perceived risk of developing a combination product 
when compared to a traditional drug or medical device. However this risk is effectively 
mitigated by the fact that the way a pioneer describes the product, its claims, and its 
intended use to the regulator is largely influenced by its core technology. For example, an 
antibiotic-coated implant may be regulated as a device or as a drug according to the 
intended use and claims. If the intended use of the antibiotic is to prevent colonization on 
the implant, then it is likely regulated as a device. If the claim says the coating prevents 
infection, it might be classified as a drug. These descriptions are strongly linked to how the 
pioneer perceives the technology and its core competence. And not surprisingly, the 
assessment of the primary mode of action correlates with the kind of company that submits 
the combination product. The additional regulatory step adds a marginal degree of 
uncertainty for the first-of-a-kind combination product relative to drugs or medical devices, 
but that uncertainty is mitigated for subsequent entrants with products in the same class. 
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5.4. Incumbents decide to market  
Our analysis suggests that incumbents leverage their stronger financial and market position 
to support product development of the first of a class of combination products, and advance 
subsequent cycles of product development for that same class.  
As product development progresses and the primary mode of action is determined, 
incumbents take-over from pioneers the role of shaping corporate partnerships. They 
license the technology from the pioneer and reshape the earlier technology-based 
partnerships to accommodate their marketing efforts as they assume control over the last 
stages of product development. Our analysis shows that big medical device and 
pharmaceutical companies supported and introduced, respectively, drug-eluting stents and 
controlled drug delivery systems to the market. We explore in detail the role of incumbents 
in the development of drug-eluting stents and transdermal patches in Box 3. 
Incumbents enter combination product development when all previous uncertainties have 
been mitigated and the only uncertainties that remain relate to traditional regulatory 
pathways, the market, distribution channels, and the service networks they have access to. 
These findings are supported by Schumpeter‟s later work, in which he stated that 
incumbents with capital and market power are in a stronger position to exploit innovation 
[32]. Different authors build on this theory. Teece identifies factors such as specialized 
manufacturing capability, access to distribution channels and service networks, and 
complementary technologies as the assets that confer incumbents with an advantage to 
exploit innovation [33].  
Once the first-of-a-kind combination product is marketed, regulation „by precedent‟ allows 
it to become a dominant standard rapidly (at technological and regulatory levels). When the 
first-of-a-kind combination product obtains marketing approval, the pathway for approval 
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is defined and the marginal uncertainty disappears, allowing other incumbents to become 
fast followers. 
 
6. Conclusions 
Combination drug-device products are a disruptive technology category in modern drug 
delivery devices, representing a unique combination of performance, design, application 
and in some cases business partnering and technology licensing.  This novel therapeutic 
product category has introduced new dynamics in medical product development, regulatory 
approval processes, and corporate interaction.  Case studies of drug-eluting stents and 
transdermal patches facilitate a detailed understanding of the challenges and opportunities 
introduced by combination products when compared to previous generations of 
conventional medical or drug delivery devices. Drug-eluting stents and transdermal patches 
represent high-value combination products, in which drug and device have both a primary 
and an ancillary function. In both cases, combination products were developed to improve 
the function of precedent, clinically approved products. 
The emergence of sophisticated combination products has brought the pharmaceutical and 
medical device industries closer; firms from each industry play now complementary roles 
in the development of drug-device products. Start-ups, new divisions of established 
companies, and incumbents from either industry interact to integrate and develop drug-
device technologies and have leveraged expertise from each other in product development, 
testing, marketing, and distribution. The new drug-device products that find a competitive 
advantage in the combination itself and yield high value combination products created a 
new market space at the intersection of the pharmaceutical and medical devices industries. 
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The emergence of these high-value combination products has triggered new regulatory, 
strategic, and technological challenges that signal a divergence from traditional drug/device 
development. Future sponsors of new combination products may perceive this divergence 
as a source of risk, particularly regulatory risk. The regulatory cornerstone is the perception 
of the assessment of the primary mode of action as an additional step in the regulatory 
process that adds product development and regulatory risk much like the subsequent phases 
of drug development. Our analysis shows that the assessment of the primary mode of action 
adds marginal risk to the development process, rather, it is consequent with the value the 
original sponsor (the pioneer) perceives in the combination and helps incumbents 
rationalize and plan the resources they will need as they take over from pioneers the task to 
bring the product to market. Indeed the assessment on the primary mode of action is a good 
proxy to understand the evolution a product will undergo throughout its development and 
the co-evolution of partnerships that will be necessary to bring this product to market; and 
because the assessment itself has thus far been predictable for the majority of products in 
the market, we may derive a simple model that overviews the expected co-evolution of 
technology and strategy for future entrants in the combination products space. 
The roles assumed by pioneer, incumbent, and regulatory agency in product development 
determine predictably the dynamics of combination products. The pioneer integrates 
complementary technologies into a new design, in so doing, it shapes the early technology-
based partnerships and informs the primary mode of action assessment. The regulator takes 
into account the submission documents to assess the primary mode of action and forward 
the product to the right center that will lead the regulatory approval as if it were a drug, a 
device or a biologic. Incumbents assume control of product development at later stages, and 
the primary mode of action informs how they may leverage their resources and existing 
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partnerships as considerations about the market, distribution channels, and service networks 
become more prevalent. Once the first-of-a-kind combination product is marketed, it 
rapidly becomes a dominant standard, allowing other incumbents to become fast followers. 
These dynamics show how may new entrants approach the introduction of a combination 
product strategically. Firms, in particular start-ups or new divisions, may use the 
complementarity of drug-device technologies to capture new market opportunities: to 
expand within the combination product market, into the drug market, or the medical device 
market. Start-ups developing a new type of combination product that overcomes the 
limitations of a single-regulated product might be able to leverage the complementary 
resources of the incumbent to accelerate the development of the combination product and 
its marketing, while acquiring the expertise to go through the entire product development 
life-cycle for future generations of the combination product. 
Expansion within the combination product space is, perhaps, the most promising area of 
development for new products. The regulatory advances in combination products, and the 
observation that the competitive advantage of current combination products lies in the 
sophistication of the combination would seem to indicate that this generation of 
combination products has established a new high-value market. The advent of new 
technologies combining drug, device, and biologics that are currently being researched 
suggests that this is a growing market. Newly emerging biomedical technologies including 
cell-based therapies, new biosimilars and fragile, expensive biologics, nanotechnologies, 
molecular diagnostics, and tissue engineering are expected to provide new opportunities in 
bridging device and drug capabilities and synergies, bringing increasingly sophisticated 
combination products to the forefront. The model here proposed can also be applied as tool 
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by start-ups and incumbents in understanding how to strategically capitalize on the 
developed of combination products.  
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Box 1. The pioneers Cordis and Alza disrupted drug-eluting stents and controlled 
drug delivery systems 
Cordis Corp. was founded in 1959, with the aim of establishing a strong business core in 
vascular disease management. In 1994 it launched the first stent to the market (PALMAZ-
SCHATZ® Balloon-Expandable Stent). In April of 2003 the FDA approved the first drug-
eluting stent developed by Cordis Corp., Cypher sirolimus-eluting coronary stent. Cordis 
Corp. was the pioneer in both generations of stents. It was a major player in interventional 
cardiology during the 1990s [24]. In 1996 Johnson & Johnson acquired it to form Cordis 
division. In this year, the interventional cardiology market was estimated at $2 billion 
worldwide, with a 20-25% annual growth rate [25]. With the support of Johnson & Johnson 
resources, Cordis was the first company to bridge both generations, upgrading the stent 
platform into a drug-eluting product.  
Alza was a pioneer and played a key role in the disruption of controlled drug delivery 
systems. Alejandro Zaffaroni founded the company in 1968. Since then, Alza developed the 
first ocular implant, the first intrauterine device, and the first transdermal patch. Based on 
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the D-Trans® platform, Alza developed the six first transdermal patches commercially 
available in the U.S. market: Transderm Scop®, Transderm-Nitro®, Catapress-TTS®, 
Estraderm®, Duragesic®, and Nicoderm®. The D-Trans® platform is a multilayer patch 
with the drug stored in a gel reservoir. Alza also had a major role in the disruption of active 
transdermal technologies. It developed the E-Trans® platform and IONSYSTM 
iontophoretic system, which was approved in 2006 by the FDA [7]. Alza sponsored the 
regulatory process under the support of the parent company, Johnson & Johnson, because, 
similarly to what happened with Cordis, Alza was acquired by Johnson & Johnson, in 2001, 
through a stock-for-stock transaction worth $10.5 billion [26].  
 
Box 2. Complementary technologies are licensed to integrate drug-eluting stents and 
transdermal patches 
In the case of drug-eluting stents, medical device companies developed the medical device 
(in blue, Fig. 3 a.) and assembled it with the drug (in red) licensed from a pharmaceutical 
company and the polymer (in yellow) typically licensed from a small company. The 
polymer works as a matrix that covers all the metallic structure and encloses the drug for 
controlled released. Medical device companies acquired or licensed the required assets to 
evolve from the first to the second generation of stents. They extended their expertise in the 
market, developing more sophisticated products. From the four different drugs used in 
drug-eluting stents currently available on the market, three were already commercially 
available as pharmaceuticals for other applications. The intellectual property licensees of 
the drugs are Wyeth (sirolimus), Novartis & AG (everolimus), Angiotech (paclitaxel), and 
Abbott Laboratories (zotarolimus).  
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In the case of transdermal patches, the companies that develop and/or manufacture the 
controlled drug delivery systems are not involved in marketing and distribution of 
pharmaceutical products. Usually there is a symbiotic interest from the pharmaceutical 
company in delivering the drug (red, in Fig. 3b.) through a transdermal system (blue) 
developed by a specialized company. The usual ways of cooperation are: (1) the patch 
platform is licensed to a pharmaceutical company and the company retains the rights of 
manufacturing or charges for the manufacturing by third parties; (2) joint development with 
pharmaceutical industry; (3) the company develops the transdermal patch and partners with 
a large pharmaceutical company for the utilization of their sales force and marketing 
expertise. Companies developing transdermal patches are typically small companies that 
build their core business in drug delivery systems. They don‟t have the resources to pursue 
clinical development by themselves and/or developing marketing and sales forces. As these 
companies are successful and expand in time, they seem to evolve from the first/second to 
the second/third forms of cooperation mentioned. Alza illustrates an example of this 
progress. Alza had commercialization and joint development agreements with Novartis, 
Boehringer Ingelheim, Janssen Pharmaceutica, and Sanofi-Aventis. After 1993, Alza 
developed, manufactured, and marketed Testoderm® and Testoderm® TTS. Alza shifted 
from being strictly a licensor to a fully integrated company, and its revenues increased from 
about $40 million in 1992 [27], to $131.2 million in 1996 [25].  
 
Box 3. The role of incumbents in the development of drug-eluting stents and 
transdermal patches  
Big medical device companies were the key actors in making the transition between bare-
metal drug-eluting stents. Besides Cordis (and Johnson & Johnson), Boston Scientific 
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Corporation, Medtronic Vascular (from Medtronic), and Abbott Vascular (from Abbott 
Laboratories) played a decisive role in disrupting drug-eluting stents. These four companies 
created a devoted division or subsidiary unit to the interventional cardiology area. The 
devoted division or subsidiary unit confers a certain independence and freedom to operate 
and develop a product that is not directly aligned with the company pipeline.  
After the approval of Cordis‟ Cypher® by the FDA in 2003, 11 other drug-eluting stents 
were released to the U.S. market, though there are only six different platforms currently in 
the market. This is illustrated in the Fig. 4. Boston Scientific has itself three platforms and 
eight different products in the market. Five of them are incremental improvements over the 
Taxus® platform. Promus® is a platform developed by Abbott‟s Xience V® Everolimus. 
This resulted from a previous agreement, when Boston Scientific acquired Guidant 
Corporation. 
Big pharmaceutical companies played an important role in the disruption of transdermal 
drug delivery systems. Indeed, 62% of the overall transdermal patches were or are 
marketed by big pharmaceutical companies. This is illustrated in Fig. 5. For example, 
Novartis launched eight different transdermal patches into the market, which resulted from 
collaborations with Alza, Noven, and Lohmann Therapie-Systems AG. Novartis also 
founded Novogyne, a joint venture with Noven, with the purpose of developing transdermal 
patches. Johnson & Johnson launched five different transdermal patches, including 
Duragesic® and IONSYS®, developed by Alza. Bayer markets three different transdermal 
patches, developed jointly with 3M Pharmaceuticals. Watson Laboratories marketed three 
different transdermal patches: two developed in collaboration with TheraTech and one 
developed in-house. Alza also launched two transdermal patches on its own, Testoderm® 
and Testoderm TTS®. The other 24 transdermal patches were individually released from 
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different entities. Big pharmaceutical companies, such as Boehringer Ingelheim, Sanofi-
Aventis, Astrazeneca, Pfizer, Bristol-Myers Squibb, and Merck & Co released a single 
transdermal patch to the market. There are two key considerations that might help 
understand why big pharmaceutical companies have only one transdermal patch. First, big 
pharmaceutical companies often seek partnerships to developed transdermal patches when 
the product can be marketed successfully within their existing portfolio. Second, the drug 
has to comply with the technical requirements to be part of a transdermal patch. When the 
two factors are aligned, big pharmaceuticals typically invest in the development of a 
transdermal patch. Also, drugs facing patent expiration can get a new life if the drug is 
combined with a device as a combination product. This solution may provide some short-
term relief to the pharmaceutical industry [30]. 
 
Fig. 1. Controlled drug delivery systems approved by the FDA: (a) Cumulative number of 
controlled drug delivery systems approved per year per type of delivery system (the legend 
is the same as for b); (b) Number of delivery systems per type approved by the FDA; (c) 
Number of delivery systems approved by the FDA by therapeutic indication. These 
numbers include market-discontinued products, but not generic forms of delivery systems. 
The number of discontinued products corresponds to approximately 38%. 
 
Fig. 2. Representation of the lessons learned in the dynamics of innovation of drug-device 
combination products from the corporate, technological, and regulatory vantage points. A 
pioneer sets the path by introducing a new technology into the combination product space. 
Complementary technologies are licensed to integrate it into a full combination product. 
The FDA determines the primary mode of action of the combination product, which is a 
AC
CE
PT
ED
 M
AN
US
CR
IP
T
ACCEPTED MANUSCRIPT
31 
crucial step that influences the company profile – medical device, pharmaceutical, or 
biopharmaceutical – that takes the product through regulatory approval into the market. 
 
Fig. 3. Schematic representation of the assembly of combination products: a. Drug-eluting 
stents are built-up on a device platform (in blue), and a drug (in red) together with a 
polymeric coating (in yellow) integrated into the device platform; b. A drug (in red) is 
integrated into a device system (in blue). Black pins represent the primary mode of action 
of the combination product. 
 
Fig. 4. Timeline showing drug-eluting stents date of approval by the FDA. Cordis‟ Cypher® was the first 
drug-eluting stent to be approved, in 2003. The second drug-eluting stent that was approved by FDA was 
Taxus® Express2® Paclitaxel-Eluting from Boston Scientific Corporation, in 2004. The following three drug-
eluting stents were approved in 2008. Medtronic Vascular‟s Endeavor® Zotarolimus eluting was approved in 
February. Xience V® Everolimus from Abbott Vascular was approved by the FDA in July. Xience V® is also 
being marketed by Boston Scientific under the name of Promus®. Taxus® Express® AtomTM and Taxus® 
Liberté® were approved by the FDA in 2008. Taxus® Liberté® AtomTM and Taxus® Liberté® LongTM were 
approved in 2009. ION™ Paclitaxel-Eluting is a new platform developed by Boston Scientific and approved 
in April 2011. Xience Nano® Everolimus from Abbott Vascular was approved by the FDA in May 2011, 
which is also being marketed by Boston Scientific under the name of Promus® 2.25. 
 
Fig. 5. Timeline showing transdermal patches date of approval by the FDA. Novartis 
launched eight different transdermal patches to the market during the last three decades, 
while Johnson & Johnson, Bayer, and Watson Labs launched 12 in aggregate during the 
last two decades.  
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